31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The pharmacokinetic basis of magnesium sulphate (Mg SO 4) dosing regimens for eclampsia prophylaxis and treatment is not clearly established.

          Objectives

          To review available data on clinical pharmacokinetic properties of Mg SO 4 when used for women with pre‐eclampsia and/or eclampsia.

          Search strategy

          MEDLINE, EMBASE, CINAHL, POPLINE, Global Health Library and reference lists of eligible studies.

          Selection criteria

          All study types investigating pharmacokinetic properties of Mg SO 4 in women with pre‐eclampsia and/or eclampsia.

          Data collection and analysis

          Two authors extracted data on basic pharmacokinetic parameters reflecting the different aspects of absorption, bioavailability, distribution and excretion of Mg SO 4 according to identified dosing regimens.

          Main results

          Twenty‐eight studies investigating pharmacokinetic properties of 17 Mg SO 4 regimens met our inclusion criteria. Most women (91.5%) in the studies had pre‐eclampsia. Baseline serum magnesium concentrations were consistently <1 mmol/l across studies. Intravenous loading dose between 4 and 6 g was associated with a doubling of this baseline concentration half an hour after injection. Maintenance infusion of 1 g/hour consistently produced concentrations well below 2 mmol/l, whereas maintenance infusion at 2 g/hour and the Pritchard intramuscular regimen had higher but inconsistent probability of producing concentrations between 2 and 3 mmol/l. Volume of distribution of magnesium varied (13.65–49.00 l) but the plasma clearance was fairly similar (4.28–5.00 l/hour) across populations.

          Conclusion

          The profiles of Zuspan and Pritchard regimens indicate that the minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted level. Exposure–response studies to identify effective alternative dosing regimens should target concentrations achievable by these standard regimens.

          Tweetable abstract

          Minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted therapeutic level.

          Tweetable abstract

          Minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted therapeutic level.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial.

          To assess the cost-effectiveness of using magnesium sulphate for pre-eclampsia to prevent eclampsia. Multinational trial-based economic evaluation. Thirty-three countries participating in the Magnesium Sulphate for Prevention of Eclampsia (Magpie) Trial. Women (9996) with pre-eclampsia from the Magpie Trial. Outcome and hospital resource use data were available for the trial period from the Magpie Trial. Country-specific unit costs (U.S. dollar, year 2001) were obtained subsequently from participating hospitals by questionnaire. Cost-effectiveness was estimated for three categories of countries grouped by gross national income (GNI) into high, middle and low GNI countries using a regression model. Uncertainty was explored in sensitivity analyses. Eclampsia, hospital care costs and the incremental cost per case of eclampsia prevented. The number of women with pre-eclampsia who needed to receive magnesium sulphate to prevent one case of eclampsia was 324 [95% confidence interval (CI) 122, infinity] in high, 184 (95% CI 91, 6798) in middle and 43 (95% CI 30, 68) in low GNI countries. The additional hospital care cost per woman receiving magnesium sulphate was $65, $13 and $11, respectively. The incremental cost of preventing one case of eclampsia was $21,202 in high, $2473 in middle and $456 in low GNI countries. Reserving treatment for severe pre-eclampsia would lower these estimates to $12,942, $1179 and $263. Magnesium sulphate for pre-eclampsia costs less and prevents more eclampsia in low GNI than in high GNI countries. Cost-effectiveness substantially improves if it is used only for severe pre-eclampsia, or the purchase price is reduced in low GNI countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Magnesium sulphate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study.

            To compare magnesium sulphate concentrations achieved by intramuscular and intravenous regimens used for the prevention of eclampsia. Low-resource obstetric hospitals in Nagpur and Vellore, India. Pregnant women at risk for eclampsia due to hypertensive disease. A pharmacokinetic study was performed as part of a randomised trial that enrolled 300 women comparing intramuscular and intravenous maintenance regimens of magnesium dosing. Data from 258 enrolled women were analysed in the pharmacokinetic study. A single sample was drawn per woman with the expectation of using samples in a pooled data analysis. Pharmacokinetic parameters of magnesium distribution and clearance. Magnesium clearance was estimated to be 48.1 dl/hour, volume of distribution to be 156 dl and intramuscular bioavailability to be 86.2%. The intramuscular regimen produced higher initial serum concentrations, consistent with a substantially larger loading dose. At steady state, magnesium concentrations in the intramuscular and intravenous groups were comparable. With either regimen, a substantial number of women would be expected to have serum concentrations lower than those generally held to be therapeutic. Clinical implications were that a larger loading dose for the intravenous regimen should be considered; where feasible, individualised dosing of magnesium sulphate would reduce the variability in serum concentrations and might result in more women with clinically effective magnesium concentrations; and lower dose magnesium sulphate regimens should be considered with caution. © 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2013 RCOG.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The use of standard dose of magnesium sulphate in prophylaxis of eclamptic seizures: do body mass index alterations have any effect on success?

              We anticipated that the universal use of a standard magnesium sulfate infusion to prevent eclamptic convulsions in preeclamptic patients would result in alterations in circulating magnesium levels that were negatively correlated with the patient's body mass index. We postulated that the highest failure rate with seizure prophylaxis would occur in patients with the highest body mass index. After discarding 6 patients, this study was performed in 194 of 200 preeclamptic patients admitted to our high risk pregnancy unit between February 2000 and August 2000, who were divided into four groups determined by body mass indices. A standard magnesium sulfate infusion protocol (loading dose 4.5 g/15 minutes followed by 1.8 g/hour) was administered to 194 preeclamptic patients. One hundred and thirty-eight severe preeclamptic patients received magnesium sulfate during both antepartum and postpartum periods. The remaining 56 patients only received the therapy during the postpartum period. Serial serum magnesium levels of each groups were recorded and compared. The 1.8 g infusion rate produced acceptable magnesium levels in the majority of patients but most were in the lower 50% of the therapeutic range. Levels were lowest in patients with high body mass indices (this group recorded most of the subtherapeutic levels, particularly when patient were infused antepartum). Apart from 13 referred patients who had convulsed prior to admission no eclampsia occurred during the antepartum period while seizures occurred in nine women during the postpartum period. Two hours after the initiation of the therapy, magnesium levels were inversely related to the body mass index (BMI) both during the ante- and postpartum periods (Prepartum; group I: 5.97 mg/dl, group II: 4.90 mg/dl, group III: 4.35 mg/dl, group IV: 3.88 mg/dl; Postpartum; group I: 5.89 mg/dl, group II: 5.71 mg/dl, group III: 4.82 mg/dl and group IV: 4.61 mg/dl, Table 4). Although the lowest levels were detected in patients with high body mass indices, in contrast to our hypothesis, eclamptic seizures occurred in four patients with low body mass indices. Furthermore therapeutic serum magnesium levels were detected in three of these patients. There was no association between treatment failures and body mass or with magnesium levels. The infusion regimen described herein resulted in therapeutic levels in the majority of patients that correlated inversely with body mass index. However most levels fell within the lower range of what many studies consider "therapeutic" suggesting that maintenance infusion rates of at least 2-2.5 g/hour would be more appropriate. This would be particularly true in patients with body mass indices exceeding 30, where subtherapeutic levels occurred most frequently. The study's limited power prevents conclusions on outcomes but what is of interest is that eclamptic convulsions did not correlate with either body mass index or circulating plasma magnesium levels.
                Bookmark

                Author and article information

                Journal
                BJOG
                BJOG
                10.1111/(ISSN)1471-0528
                BJO
                Bjog
                John Wiley and Sons Inc. (Hoboken )
                1470-0328
                1471-0528
                24 November 2015
                February 2016
                : 123
                : 3 ( doiID: 10.1111/bjo.2016.123.issue-3 )
                : 356-366
                Affiliations
                [ 1 ] Experimental and Maternal Medicine (EMM) Unit Department of Obstetrics and Gynaecology College of MedicineUniversity of Lagos Idi‐Araba LagosNigeria
                [ 2 ] UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research Development and Research Training in Human Reproduction (HRP) Department of Reproductive Health and ResearchWorld Health Organization GenevaSwitzerland
                [ 3 ] Department of Obstetrics and Gynaecology Faculty of MedicineKhon Kaen University Khon KaenThailand
                [ 4 ]Centro Rosarino de Estudios Perinatales RosarioArgentina
                [ 5 ] Department of Obstetrics and Gynaecology School of Medicine College of Health SciencesUniversity of Nairobi NairobiKenya
                [ 6 ] Nottingham Clinical Trials UnitQueens Medical Centre NottinghamUK
                [ 7 ] Department of Social Medicine Ribeirao Preto School of MedicineUniversity of Sao Paulo Ribeirao Preto São PauloBrazil
                Author notes
                [*] [* ] Correspondence: Dr OT Oladapo, UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research, World Health Organization, Avenue Appia 20, Geneva 27, CH‐1211 Switzerland. Email oladapoo@ 123456who.int
                Article
                BJO13753
                10.1111/1471-0528.13753
                4737322
                26599617
                f09bb880-0d3c-493e-be33-b402f76786b4
                © 2015 World Health Organization; licensed by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

                This is an open access article distributed under the terms of the Creative Commons Attribution IGO License which permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.

                History
                : 22 September 2015
                Page count
                Pages: 11
                Funding
                Funded by: Merck
                Funded by: Merck‐for‐Mothers Programme
                Funded by: UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research
                Funded by: Development and Research Training in Human Reproduction (HRP)
                Funded by: Department of Reproductive Health and Research
                Funded by: World Health Organization
                Categories
                Systematic Review
                Systematic Reviews
                Custom metadata
                2.0
                bjo13753
                February 2016
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.5 mode:remove_FC converted:28.01.2016

                Obstetrics & Gynecology
                eclampsia,magnesium sulphate,pharmacokinetics,pre‐eclampsia,serum magnesium

                Comments

                Comment on this article